Table 3 Detailed study procedures in the bioavailability study (30 mL single dose)

Time Point, week

Up to -12

2

7

12

Informed consent form

X

Randomization & allocation

X

Treatment distribution

X

X

X

Blood collection at baseline (0 h) and at 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h after oils ingestion

X

X

X

Urine collection at baseline (0 h) and at

0–2 h, 2–4 h, 4–6 h, 6–8 h, 8–10 h, 10–12 h, 12–24 h, after oils ingestion

X

X

X

  Urinary tyrosol and hydroxytyrosol at 0–2 h, 2–4 h, 4–6 h, 6–8 h, 8–10 h, 10–12 h, 12–24 h, after oils ingestion

X

X

X

  Plasma Triterpenes at baseline (0 h) and at 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h after oils ingestion

X

X

X

  Endothelial function measurements at baseline (0 h) and at 4 h, and 6 h, after oils ingestion

X

X

X

  Plasma gastrointestinal hormones t baseline (0 h) and at 2 h, 4 h, and 6 h, after oils ingestion

X

X

X